Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02075918
Other study ID # 12-2016
Secondary ID 1U01AA021908-01
Status Completed
Phase
First received
Last updated
Start date May 2014
Est. completion date May 31, 2019

Study information

Verified date June 2019
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Purpose: To improve the diagnosis and assessment of severity of acute alcoholic hepatitis Participants: Patients admitted to one of ten centers with acute alcoholic hepatitis Procedures (methods): Consecutive patients admitted with acute alcoholic hepatitis will be enrolled in an NIH U01 study of acute alcoholic hepatitis where liver tissue, blood and stool will be collected to discover and validate factors associated with diagnosis, severity of disease and survival.


Description:

The development of new targeted therapies for alcoholic hepatitis (AH) is one of the more urgent needs in clinical hepatology. To reach this goal, large multidisciplinary networks are required. The proposed initiative "Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis" (InTeam) will coordinate a multidisciplinary group composed of clinicians, physician-scientists, basic scientists and bioinformatics experts. The overarching hypothesis of InTeam is that the most rational way to provide a useful framework for future clinical trials in (AH) consists of the (i) determination of key drivers of the disease process, (ii) classification of molecular profiles and subtypes of AH, and (iii) identification of "druggable" targets based on both key drivers and molecular classification. Moreover, mouse models for AH are lacking making it impossible to evaluate promising targets in preclinical mouse studies in a meaningful manner. For this purpose, InTeam will integrate data obtained from molecular pathology studies in human AH and functional studies of key pathways in animal models. The proposed InTeam consortium includes three research projects, ten clinical centers, a Human Biorepository and a Mouse Models Core. The Human Biorepository Core will generate the to-date largest collection of samples from patients with AH from 10 academic liver centers and a comprehensive database that will serve as a basis for the proposed translational studies and be a valuable asset for the broader scientific community. The Mouse Models core will conduct murine studies after establishing and evaluating mouse models of AH based on the pathophysiology and molecular drivers of human AH determined by this consortium.


Recruitment information / eligibility

Status Completed
Enrollment 376
Est. completion date May 31, 2019
Est. primary completion date May 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients 18 = and = 70 years of age.

- Active alcohol abuse within the past 3 months.

- Has an Aspartate Aminotransferase (AST) > Alanine Aminotransferase (ALT).

- Elevated Total Bilirubin level > 3.0.

- Absence of autoimmune liver disease (ANA>1/320).

- Absence of hepatitis B infection.

- A liver biopsy, and/or a clinical picture consistent with alcoholic hepatitis.

- The "Start Date" (is the date of the liver biopsy or = to 1 week [72 hours is preferred] from the time of admission).

Exclusion Criteria:

- Hepatocellular carcinoma.

- Complete portal vein thrombosis.

- Advanced or terminal extrahepatic diseases.

- Lack of consent to participate in the study.

- Pregnancy.

- Received more than 3 days of treatment with (prednisolone or pentoxifyllin) prior to start date.

Control patients

Study Design


Locations

Country Name City State
United States University of Pittsburgh Pittsburgh Pennsylvania

Sponsors (12)

Lead Sponsor Collaborator
University of Pittsburgh Columbia University, Hospital San Jose Tec de Monterrey, Hospital Vall d'Hebron, Institut National de la Santé Et de la Recherche Médicale, France, King's College London, National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Alberta, University of Wisconsin, Madison, Veterans Medical Research Foundation, Weill Medical College of Cornell University, Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnosis and Severity of Alcoholic Hepatitis Utilizing liver tissue, blood samples, and stool and urine samples, InTeam will aim to discover and validate factors associated with the diagnosis and severity of Alcoholic hepatitis. 3 months after end of Study
Secondary Major Liver Complications As an observational study, we will collect data regarding major liver complications such as, ascites, renal failure, encephalopathy, and bleeding. 3 months after end of study
Secondary Death/Transplantation As an observational study, we will collect the data regarding number the survival of Alcoholic Hepatitis by considering deaths and transplantations. 3 months after end of study
See also
  Status Clinical Trial Phase
Recruiting NCT04066179 - Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients. N/A
Completed NCT03732586 - Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis N/A
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT00962442 - N-Acetylcysteine in Severe Acute Alcoholic Hepatitis Phase 3
Not yet recruiting NCT06307522 - MRG-001 in Patients With Alcoholic Hepatitis Phase 2
Recruiting NCT05018481 - HA35 Moderate Alcoholic Hepatitis (AH) Study Early Phase 1
Completed NCT04544020 - Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
Recruiting NCT04088370 - Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
Completed NCT04235855 - EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication? N/A
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed NCT00851981 - Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease Phase 2
Completed NCT04084522 - Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis N/A
Completed NCT05840640 - Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis Phase 4
Recruiting NCT03069300 - N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis Phase 3
Terminated NCT02039219 - Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Phase 2
Completed NCT02019056 - Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis Phase 2
Completed NCT01245257 - Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis N/A
Completed NCT00388323 - Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human N/A
Recruiting NCT03845205 - Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH N/A
Recruiting NCT03703674 - GCSF in Alcoholic Hepatitis Phase 4